• Aged 18 years and above, with no gender restrictions;

• Pathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records indicating metastatic pancreatic cancer, with metastasis limited to the liver;

• Clinical records indicating previous failure of standard AG treatment (having received at least one cycle of standardized chemotherapy, with disease progression or intolerance during treatment, or disease progression after the end of treatment);

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;

• Adequate organ function, meeting the following criteria:

• a. Hematological tests:

⁃ Neutrophils ≥ 1.5 × 10⁹ /L;

⁃ White blood cells ≥ 3.0 × 10⁹ /L;

⁃ Platelets ≥ 85 × 10⁹ /L;

⁃ Hemoglobin ≥ 70 g/L; b. Biochemical tests:

• <!-- -->

‣ Total bilirubin ≤ 2× upper limit of normal (ULN) (for subjects with biliary obstruction, after biliary drainage ≤ 2.5 × ULN);

⁃ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in metastatic subjects ≤ 5 × ULN;

⁃ Albumin level ≥ 28 g/L;

⁃ Creatinine clearance rate ≥ 60 ml/min; c. Cardiac function tests:

• <!-- -->

‣ Normal electrocardiogram (ECG) or ECG abnormalities deemed clinically insignificant by the investigator;

⁃ Left ventricular ejection fraction (LVEF) ≥ lower limit of normal;

• At least 3 weeks post-surgery, radiotherapy, chemotherapy, or other anti-tumor treatments, with general physical condition or related adverse reactions having recovered (toxicity ≤ grade 1) or stabilized;

• Willing to participate and sign the informed consent form;

• Good compliance and agreement to cooperate with survival follow-up.